EQT

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Established in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies in sectors such as healthcare, technology, industrials, and services. EQT employs a responsible ownership approach and an industrial growth strategy, seeking opportunities in regions with significant growth potential, including Northern and Eastern Europe, Asia, and the United States. The firm invests through various strategies, including private capital, real assets, credit, and public value, and aims to acquire controlling or co-controlling stakes in its portfolio companies, often holding investments for four to eight years. EQT Life Sciences, a notable segment of the firm, targets innovative healthcare and life sciences companies.

CHRISTIAN SHIN HØEGH ANDERSEN

Managing Director, Private Equity & Investment Advisory Professional

James Arrol

Managing Director, Fund Management

Teruyuki Asaoka

Managing Director

Peter Henrik Balslev

Managing Director

Johann-Christoph Balzer

Partner, EQT Value-Add Infrastructure

Michael Bauer

Partner, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Eirik Benzon

Managing Director, BPEA EQT Team

William Bergström

Director

Mark Braganza

Partner, Investment Advisory

Marcus Brennecke

Institutional Partner,Marcus is a member of the Equity Partners Investment Committee and the Portfolio Performance Review Committee

Carolina Brochado

Deputy Head, Advisory Team

Drew Burdon

Partner

Caspar Callerström

Partner

Kenneth Cheong

Partner

Crosby Cook

Partner, Infrastructure & Investment Advisory Professional

Guy Cui

Partner

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Mads M. Ditlevsen

Partner & Head of EQT Partners Denmark

Asís Echániz

Partner & Head of Spain

Frederik Elwing

Managing Director

Leeann Emmi

Vice President

Victor Englesson

Partner, Head of Private Equity Nordic and Co-Head of Global Technology Sector

Ali Farahani

Partner

Michael Focking

Senior Partner

Mark Fogle

Partner & Head of EQT Exeter APAC

Per Franzén

Head of Private Capital and Deputy Managing Partner

Joseph Fuda

Partner, Client Relations and Capital Raising

Florian Funk

Partner, Private Equity

Maria Gaffron

Associate, Infrastructure

Guillermo Garcia-Barrero

Managing Director

Henrik Giver

Managing Director

Hari Gopalakrishnan

Partner & Global Co-Head of Services, Private Capital

Wolfgang Gorny

Partner, Private Equity

Alexander Greenbaum

Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional

Fabian Gröne

Partner, Infrastructure

Albert Gustafsson

Chief Operating Officer of Private Capital Europe & North America

Floris van Halder

Managing Director

Sean Ham

Partner & Head of Asia Pacific

Kevin Hammon

Associate

Adil Haque

Partner & Co-Head, Client Relations, Capital Raising & Fundraising

Takanobu Hara

Partner

Jerry He

Partner & Head of China, Mid Market Asia Advisory Team

Frank Heckes

Partner, Private Equity

Erika Henriksson

Partner, Private Equity

Jak Hestnes

Managing Director and Board Member

Gerran Ho

Managing Director, Mid Market Asia

Clara Ho

Head of Business Development, Private Capital Asia

Christian Horn

Managing Director

Andreas Huber

Partner, Vice Chairman, Asia Pacific and member of the Infrastructure Partners Investment Committee

Sara Huda

Managing Director & Head of Investment Services

Johan Daniel Hylander

Managing Director

Bert Janssens

Head of Private Equity Europe & Global Co-Head of Services, Private Capital

Bjorn Jensen

Partner

Yan Jiao

Partner

Hakan Johansson

Senior Partner

Kosmo Kalliarekos

Partner

Masahiko Kato

Managing Director & Head of Infrastructure Japan

Nils Ketter

Partner

Paul Kim

Managing Director

Jörg Kinberger

Partner, Private Equity

Thomas Klews

Director

Thomas von Koch

Partner

Vesa Koskinen

Partner, Private Equity & Head of Finland

Gleb Kozyritskiy

Managing Director

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Elias Nissilä Källström

Managing Director

Tobias Küng

Managing Director, Infrastructure

Priscilla Lam

Managing Director, Portfolio Monitoring

Lance Lan

Managing Director, Exit Management

Adam Larsson

Managing Director

Edward Lavish

Managing Director, Portfolio Risk and Transactions

Eu Han Lee

Partner, Debt Capital Markets

Alex Lee

Partner

Hong Yong Leong

Partner

Janice Leow

Partner

Gebhard Littich

Managing Director

Nicholas Macksey

Partner

Tadashi Maruoka

Partner

Axel Masucci

Managing Director

Arnav Mitra

Director

Mikael Moll

Managing Director, Public Value

Jens Moritz

Partner

Tomasz Muszynski

Director, Private Equity

Petri Myllyneva

Partner

Alex Paganini

Associate, Infrastructure

Sydney Pardey

Managing Director

Tyler Parker

Managing Director

Daniel Perez

Partner

Christopher J. Popp

Managing Director

Shane Predeek

Partner

Federico Quitadamo

Partner & Head of Italy

Vai Rajan

Head of EMEA Private Wealth Capital Raising & Director - Client Relations & Capital Raising

Thomas Rajzbaum

Managing Director & Partner, EQT Infrastructure

Hermann Rauch

Managing Director

Vera Rebanova

Partner, Client Relations and Capital Raising

Johannes Reichel

Partner, Co-Head of Technology, Private Equity

Matthias Riefer

Managing Director, Private Equity

Maxwell Roitstein

Associate

Joachim Rothe Ph.D

Managing Partner

Joakim Rubin

Partner

Isidoor Rutten

Partner

Rob Ryan

Managing Director, Market Risk

Rosa Sammon, Darlene De La

Partner and Co-Head, Client Relations and Capital Raising

Anthony Santospirito

Partner

Matthew Scattarella

Partner

Paul Schrotti

Partner

Hemant Sharma

Managing Director

Gordon Shaw

Partner

Piyush Singhvi

Managing Director, Infrastructure

Carl Sjölund

Partner, Infrastructure

Jared Small

Managing Director

Georg Stadler

Partner, Infrastructure

Francesco Starace

Partner

Joshua Stone

Managing Director, FO Head of Strategic Initiatives

Alexander Strassburger

Managing Director

Marc-Alexander Straubinger

Managing Director

Anna Sundell

Partner, Infrastructure

Miriam Tawil

Partner & Investment Advisory Professional

Michiel Thiessen

Managing Director

Elly Thio

Managing Director

Matteo Thun

Partner

Wei Jian Tor

Managing Director

Juan Diego Vargas

Partner

Marcus Wallinder

Partner & Deputy Head of Client Relations and Capital Raising

Forrest Wang

Managing Director, Private Equity

Ethan Waxman

Partner

Arno de Wilde

Investor

Rickard Wilson

Managing Director

Matthias Wittkowski

Partner

Ken Wong

Partner and Head of Asia Pacific, Infrastructure

Philipp R. Wörner

Director, Private Equity

Dayea Yeon

Managing Director and Head of Private Capital Korea

Shuting You

Managing Director

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

Managing Director, Infrastructure

Stephan Leithner Ph.D

Partner

Past deals in Netherlands

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Storytel

Post in 2021
Storytel AB provides streaming services for audiobooks and e-books through subscription models, operating under the Storytel and Mofibo brands. Founded in 2005, the company has established itself as a leader in this sector across various countries, including Sweden, Norway, Denmark, Finland, the Netherlands, Poland, Germany, Spain, and India, among others. In addition to its streaming services, Storytel publishes audiobooks primarily through its own publisher, Storyside, and has expanded its reach in the publishing industry by acquiring several publishing houses such as Massolit and B. Wahlström. The company also offers digital subscriptions for newspapers and magazines and publishes physical books through notable imprints like Norstedts and Rabén & Sjögren. Headquartered in Stockholm, Sweden, Storytel continues to enhance its offerings in the growing digital reading and listening market.

Mollie

Series C in 2021
Mollie B.V. is a payments platform that specializes in online payment processing for merchants. Founded in 2004 and headquartered in Amsterdam, the Netherlands, Mollie serves over 50,000 clients by providing an easy-to-implement solution for integrating various payment methods into websites and applications. The platform supports a wide range of local payment options, including Mastercard, VISA, PayPal, iDEAL, and Bitcoin, among others. Mollie focuses on simplifying the payment process for merchants, eliminating complexities associated with multiple payment methods through a powerful and user-friendly API. The company emphasizes technology, innovation, and reliability in its services.

Onward

Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Vico Therapeutics

Series A in 2020
Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company focuses on conditions such as spinocerebellar ataxias, Huntington's disease, and Rett syndrome. By leveraging innovative approaches to RNA therapy, Vico Therapeutics aims to address the unmet medical needs of patients with central nervous system disorders, particularly those that are hereditary or neurodevelopmental in nature. The company is committed to discovering, developing, and delivering effective treatments to improve the quality of life for individuals affected by these conditions.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

VarmX

Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

Kiadis Pharma

Post in 2020
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Pharvaris

Series B in 2019
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

AM Pharma

Series F in 2019
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Dunlop Protective Footwear

Acquisition in 2018
Dunlop Protective Footwear is the leading global manufacturer of protective wellington boots. In more than 50 countries worldwide, the Company provides comfortable and protective footwear to the workers in Agriculture & Fishery, Food processing, Industry and the Oil, Gas & Mining industry. Dunlop has more than 500 employees, three production sites in the Netherlands, Portugal and the US, and sales people around the world. Dunlop Protective Footwear is headquartered in Raalte, the Netherlands.

Merus

Post in 2018
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Caiway

Acquisition in 2017
Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband, television, and telephony services. The company operates broadband connections to over 350,000 households and businesses, focusing on both urban and remote areas. In recent years, Caiway has expanded its fiber networks to enhance connectivity in municipalities and homes, establishing itself as a strong regional internet service provider. Key regions within Caiway's service area include Westland, Schiedam, and Almelo. By leveraging advanced cable and fiber infrastructure, Caiway aims to deliver reliable networking and high-quality services to its customers.

Xeltis

Series C in 2017
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Dentconnect

Acquisition in 2017
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

DELTA NV

Acquisition in 2016
Delta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands.

TransIP

Private Equity Round in 2016
TransIP Group B.V. provides virtual private servers, domain name registration, and Web hosting services to customers and information technology professionals. The company offers BladeVPS PureSSD Pro, a self-managed tool that contains Web control panels and operating systems; STACK, an online storage solution for storing, syncing, and sharing various files, photos, and documents; and SSL certificates that encrypt the connection between a Website and the server. It also offers forwarding, big storage, and private network services. The company was founded in 2003 and is based in Leiden, the Netherlands. As of May 23, 2019, TransIP Group B.V. operates as a subsidiary of Combell nv.

Mint Solutions

Series B in 2016
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Onward

Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

ViCentra

Series B in 2016
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Pharvaris

Series A in 2016
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis

Series B in 2015
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Merus

Series C in 2015
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Xeltis

Series B in 2014
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Bureau van Dijk

Acquisition in 2014
Bureau van Dijk is best known for our range of company information products that is co-published with many renowned information providers (IPs).

Mint Solutions

Series A in 2014
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Merus

Series B in 2013
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kiadis Pharma

Venture Round in 2012
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Prosensa

Venture Round in 2012
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

ATOS MEDICAL

Acquisition in 2011
Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Koole Terminals

Acquisition in 2011
Koole is an independent international storage and transport company specialising in vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals and minerals.

Kreatech Diagnostics

Series B in 2010
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

Merus

Series B in 2010
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kreatech Diagnostics

Venture Round in 2009
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

BMEYE

Series A in 2009
BMEYE B.V. is a non-invasive cardiovascular monitoring company based in Amsterdam, Netherlands, specializing in the research and development of medical technologies for cardiovascular assessment. The company offers a range of innovative products, including the Finapres, a continuous finger blood pressure monitor, and the Portapres, an ambulatory version of the same technology. Additionally, BMEYE provides the Finometer, which can measure non-invasive brachial pressure and beat-to-beat hemodynamics, along with BeatScope, a software for analyzing arterial pressure waveforms. Other notable products include Modelflow, which computes aortic flow waveform and cardiac output from arterial blood pressure waveforms, and the Nexfin monitor, which measures blood pressure and cardiac output for various medical applications. BMEYE serves a diverse range of fields, including cardiology, anesthesiology, and neurology, through a network of distributors. Founded in 2005, the company was later acquired by Edwards Lifesciences.

Kiadis Pharma

Venture Round in 2007
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Prosensa

Series A in 2007
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

BMEYE

Series A in 2006
BMEYE B.V. is a non-invasive cardiovascular monitoring company based in Amsterdam, Netherlands, specializing in the research and development of medical technologies for cardiovascular assessment. The company offers a range of innovative products, including the Finapres, a continuous finger blood pressure monitor, and the Portapres, an ambulatory version of the same technology. Additionally, BMEYE provides the Finometer, which can measure non-invasive brachial pressure and beat-to-beat hemodynamics, along with BeatScope, a software for analyzing arterial pressure waveforms. Other notable products include Modelflow, which computes aortic flow waveform and cardiac output from arterial blood pressure waveforms, and the Nexfin monitor, which measures blood pressure and cardiac output for various medical applications. BMEYE serves a diverse range of fields, including cardiology, anesthesiology, and neurology, through a network of distributors. Founded in 2005, the company was later acquired by Edwards Lifesciences.

DNage

Series A in 2005
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

OctoPlus

Series B in 2005
OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.

PamGene

Series B in 2003
PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

PamGene

Series A in 2000
PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

Haanpaa

Acquisition in 1999
Haanpaa provides trucks that distribute chemical products across Europe. It offers services in their storage, maintenance, transportation, and delivery in several European cities. Haanpaa specializes as well in sampling, monitoring, and packaging chemical products. Moreover, it provides tank inspection and customer services. Haanpaa produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, agricultural commodities, and other products. Jussi Haanpaa founded Haanpaa in 1949, with its headquarters in Vantaa in Finland. Haanpaa has branches in Oulu and Hamina in Finland; Helsingborg and Göteborg in Sweden, Fredrikstad in Norway, Tallinn in Estonia, Saint Petersburg and Moscow in Russia, and Barendrecht in the Netherlands. It now operates as a subsidiary of Groupe Samat SA since July 12, 2016.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.